Bayer is cutting manufacturing jobs as part of a bigger restructuring. (Bayer)
Several years back, Bayer Healthcare was feeling so good about the future of its hemophilia treatments that it announced plans to invest $700 million in two plants in Germany and hire 500 workers by 2020. Fast-forward four years, and one of those plants will be now be closed and hundreds of workers there let go.
Bayer last week announced it will close its hemophilia manufacturing facility in Wuppertal, Germany, and lay off 350 workers. It will now focus all of its recombinant factor VIII production at its site in Berkeley, California. The cuts in Germany come on top of the announced layoffs in October of more than 225 manufacturing workers in Berkeley.